Indoco Remedies Limited (INDOCO.NS)
INR 229.66
(-1.25%)
INR 229.66
(-1.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 21.44 Billion INR | 29.34% |
| 2022 | 16.58 Billion INR | 11.58% |
| 2021 | 14.86 Billion INR | 13.01% |
| 2020 | 13.15 Billion INR | 3.42% |
| 2019 | 12.71 Billion INR | 1.08% |
| 2018 | 12.58 Billion INR | 1.76% |
| 2017 | 12.36 Billion INR | 3.28% |
| 2016 | 11.96 Billion INR | 24.2% |
| 2015 | 9.63 Billion INR | 13.97% |
| 2014 | 8.45 Billion INR | 15.93% |
| 2013 | 7.29 Billion INR | 5.81% |
| 2012 | 6.89 Billion INR | 5.02% |
| 2011 | 6.56 Billion INR | 16.26% |
| 2010 | 5.64 Billion INR | 17.85% |
| 2009 | 4.79 Billion INR | 15.24% |
| 2008 | 4.15 Billion INR | 0.0% |
| 2006 | 3.47 Billion INR | 11.69% |
| 2005 | 3.1 Billion INR | 9.05% |
| 2004 | 2.84 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 23.89 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 21.44 Billion INR | 29.34% |
| 2023 Q2 | 19.38 Billion INR | 0.0% |
| 2023 Q4 | 21.44 Billion INR | 0.0% |
| 2022 Q4 | 16.58 Billion INR | 0.0% |
| 2022 FY | 16.58 Billion INR | 11.58% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 16.65 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 14.86 Billion INR | 13.01% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 14.86 Billion INR | 0.0% |
| 2021 Q2 | 14.32 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 13.7 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 13.15 Billion INR | 0.0% |
| 2020 FY | 13.15 Billion INR | 3.42% |
| 2019 FY | 12.71 Billion INR | 1.08% |
| 2019 Q4 | 12.71 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 13.1 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 FY | 12.58 Billion INR | 1.76% |
| 2018 Q4 | 12.58 Billion INR | 0.0% |
| 2017 FY | 12.36 Billion INR | 3.28% |
| 2016 FY | 11.96 Billion INR | 24.2% |
| 2015 FY | 9.63 Billion INR | 13.97% |
| 2014 FY | 8.45 Billion INR | 15.93% |
| 2013 FY | 7.29 Billion INR | 5.81% |
| 2012 FY | 6.89 Billion INR | 5.02% |
| 2012 Q4 | 6.91 Billion INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2011 FY | 6.56 Billion INR | 16.26% |
| 2010 FY | 5.64 Billion INR | 17.85% |
| 2009 FY | 4.79 Billion INR | 15.24% |
| 2008 FY | 4.15 Billion INR | 0.0% |
| 2006 FY | 3.47 Billion INR | 11.69% |
| 2005 FY | 3.1 Billion INR | 9.05% |
| 2004 FY | 2.84 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 3.66 Billion INR | -484.601% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -4455.24% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 20.488% |
| FDC Limited | 24.68 Billion INR | 13.102% |
| Gufic Biosciences Limited | 10.92 Billion INR | -96.306% |
| Hikal Limited | 24.87 Billion INR | 13.767% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -84.08% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 4.441% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -793.408% |
| Medico Remedies Limited | 961.95 Million INR | -2129.558% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 2.114% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -2010.724% |
| RPG Life Sciences Limited | 5.12 Billion INR | -318.182% |
| Sequent Scientific Limited | 15.4 Billion INR | -39.233% |
| Shilpa Medicare Limited | 30.93 Billion INR | 30.663% |
| Sigachi Industries Limited | 6.94 Billion INR | -208.969% |
| Themis Medicare Limited | 5.66 Billion INR | -278.649% |
| Unichem Laboratories Limited | 31.69 Billion INR | 32.329% |
| Venus Remedies Limited | 6.26 Billion INR | -242.155% |
| Wanbury Limited | 3.43 Billion INR | -524.388% |
| ZIM Laboratories Limited | 4.46 Billion INR | -379.996% |
| Lupin Limited | 239.97 Billion INR | 91.063% |
| Innova Captab Limited | 13.2 Billion INR | -62.371% |
| Ind-Swift Limited | 6.54 Billion INR | -227.704% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -180.31% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 95.241% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 8.603% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -98.949% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -543.244% |
| Morepen Laboratories Limited | 12.93 Billion INR | -65.846% |
| Laurus Labs Limited | 83.87 Billion INR | 74.428% |
| Aarti Drugs Limited | 24.32 Billion INR | 11.825% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 24.757% |
| Alembic Limited | 23.28 Billion INR | 7.903% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 66.726% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 85.063% |
| Vaishali Pharma Limited | 799.55 Million INR | -2582.398% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 16.939% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -888.0% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 81.428% |
| Eris Lifesciences Limited | 70.48 Billion INR | 69.573% |
| Windlas Biotech Limited | 6.26 Billion INR | -242.496% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 97.49% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -206.263% |
| Orchid Pharma Limited | 15.53 Billion INR | -38.025% |
| Albert David Limited | 4.97 Billion INR | -330.676% |
| Hester Biosciences Limited | 6.62 Billion INR | -223.808% |
| Sakar Healthcare Limited | 3.88 Billion INR | -451.828% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 4.851% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -169.995% |
| Divi's Laboratories Limited | 154.7 Billion INR | 86.136% |
| Mankind Pharma Limited | 119.63 Billion INR | 82.072% |
| Neuland Laboratories Limited | 18.32 Billion INR | -17.035% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 46.303% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 92.675% |
| Wockhardt Limited | 76.49 Billion INR | 71.961% |
| Bal Pharma Limited | 3.2 Billion INR | -569.414% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 94.465% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -76.686% |
| Alkem Laboratories Limited | 155.74 Billion INR | 86.23% |
| Valiant Laboratories Limited | 3.42 Billion INR | -525.856% |
| Ajanta Pharma Limited | 46.38 Billion INR | 53.761% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -1352.266% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -603.208% |
| Granules India Limited | 55.2 Billion INR | 61.153% |
| Medicamen Biotech Limited | 2.94 Billion INR | -628.206% |
| Ipca Laboratories Limited | 111.01 Billion INR | 80.68% |
| Brooks Laboratories Limited | 904.45 Million INR | -2271.298% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -430.003% |
| Piramal Enterprises Limited | 826.05 Billion INR | 97.404% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 85.76% |
| NATCO Pharma Limited | 69.06 Billion INR | 68.945% |
| Suven Life Sciences Limited | 2.84 Billion INR | -652.794% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -1103.723% |
| Strides Pharma Science Limited | 58.39 Billion INR | 63.274% |
| Alpa Laboratories Limited | 1.82 Billion INR | -1074.411% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -1321.587% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -316.42% |